- Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial
- Updated deep B cell depletion and clinical response data is consistent with previously reported findings; however, updated longer-term data showed that durability of clinical response did not meet the threshold the Company required to support continued development
- Company shares details of two recent Grade 5 events, consisting of a case of leukoencephalopathy assessed as likely fludarabine toxicity, and a second event assessed as unrelated to any component of the study treatment
- Company reducing its workforce by approximately 94% and evaluating strategic alternatives; Leerink Partners engaged as financial advisor
- Cash, cash equivalents and investments of approximately $319.1 million (preliminary and unaudited) as of September 30, 2026
SAN DIEGO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva or the Company), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that it will discontinue further development of AlloNK® (AB-101), its non-genetically modified, allogeneic NK cell therapy candidate being evaluated in combination with rituximab in rheumatoid arthritis (RA) and other B-cell-driven autoimmune diseases. The decision follows the Company’s review of the overall risk-benefit in the context of updated clinical data, including longer-term follow-up, and recent Grade 5 safety events. The Company also announced that it is implementing a reduction in workforce and evaluating strategic alternatives to maximize stockholder value that may include a merger, business combination, sale or licensing of assets, or dissolution and liquidation.